MX2022011811A - Metodos y tratamiento con exceso de light libre. - Google Patents

Metodos y tratamiento con exceso de light libre.

Info

Publication number
MX2022011811A
MX2022011811A MX2022011811A MX2022011811A MX2022011811A MX 2022011811 A MX2022011811 A MX 2022011811A MX 2022011811 A MX2022011811 A MX 2022011811A MX 2022011811 A MX2022011811 A MX 2022011811A MX 2022011811 A MX2022011811 A MX 2022011811A
Authority
MX
Mexico
Prior art keywords
light
conditions
methods
free light
treatment involving
Prior art date
Application number
MX2022011811A
Other languages
English (en)
Inventor
Garry A Neil
Inbal Zafir-Lavie
Original Assignee
Avalo Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avalo Therapeutics Inc filed Critical Avalo Therapeutics Inc
Publication of MX2022011811A publication Critical patent/MX2022011811A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • General Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)

Abstract

La presente divulgación se refiere a métodos para detectar LIGHT libre (activa) en muestras biológicas para diagnosticar afecciones asociadas con LIGHT libre elevada, además para predecir la eficacia de los tratamientos anti-LIGHT. La divulgación también se refiere al tratamiento de tales afecciones con anticuerpos anti-LIGHT. Las afecciones incluyen lesión pulmonar aguda (ALI) y dificultad respiratoria aguda (ARDS), opcionalmente en donde ALI y ARDS se asocian con una infección viral, que incluye la infección por coronavirus. Las afecciones además incluyen la enfermedad de Crohn o una afección inflamatoria asociada con la enfermedad de Crohn.
MX2022011811A 2020-04-01 2021-03-31 Metodos y tratamiento con exceso de light libre. MX2022011811A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063003826P 2020-04-01 2020-04-01
US202063027127P 2020-05-19 2020-05-19
US202163133636P 2021-01-04 2021-01-04
PCT/US2021/025068 WO2021202649A2 (en) 2020-04-01 2021-03-31 Methods and treatment involving excess free light

Publications (1)

Publication Number Publication Date
MX2022011811A true MX2022011811A (es) 2022-10-07

Family

ID=77929895

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011811A MX2022011811A (es) 2020-04-01 2021-03-31 Metodos y tratamiento con exceso de light libre.

Country Status (11)

Country Link
US (2) US11708406B2 (es)
EP (1) EP4126945A4 (es)
JP (1) JP7542077B2 (es)
KR (2) KR20240135067A (es)
CN (1) CN115768791B (es)
AU (1) AU2021248833A1 (es)
BR (1) BR112022019112A2 (es)
CA (1) CA3173873A1 (es)
MX (1) MX2022011811A (es)
TW (1) TW202204405A (es)
WO (1) WO2021202649A2 (es)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140467A (en) 1997-07-07 2000-10-31 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US6998108B1 (en) 1997-07-07 2006-02-14 La Jolla Institute For Allergy And Immunology Antibodies to p30 polypeptides and methods making and using same
US7118742B2 (en) 1997-07-07 2006-10-10 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
AU5338701A (en) 2000-04-12 2001-10-30 Jolla Inst Allergy Immunolog Ligand for herpes simplex virus entry mediator and methods of use
US8153123B2 (en) 2004-12-09 2012-04-10 La Jolla Institute For Allergy And Immunology Method for restoring dendritic cell populations
US8349320B2 (en) 2004-12-09 2013-01-08 La Jolla Institute For Allergy And Immunology Compositions and methods for modulating responses mediated or associated with BTLA activity
US8058402B2 (en) 2006-08-28 2011-11-15 Kyowa Hakko Kirin Antagonistic human LIGHT-specific human monoclonal antibodies
SI2292663T1 (sl) * 2006-08-28 2014-02-28 Kyowa Hakko Kirin Co., Ltd Antagonistična humana monoklonska protitelesa, specifična za humani LIGHT
US8263081B2 (en) 2007-05-14 2012-09-11 The University Of Chicago Antibody-light fusion products for cancer therapeutics
JP2010539243A (ja) 2007-09-18 2010-12-16 ラ ホヤ インスティテュート フォア アラージー アンド イムノロジー 喘息、肺及び気道の炎症、呼吸器、間質性、肺性および線維性疾患の処置のためのｌｉｇｈｔ阻害剤
US9700606B2 (en) 2008-07-08 2017-07-11 La Jolla Institute For Allergy And Immunology HVEM/BTLA, HVEM/CD 160 and HVEM/gD cis complexes and methods of use
CA2756186A1 (en) 2009-03-24 2010-09-30 Teva Biopharmaceuticals Usa, Inc. Humanized antibodies against light and uses thereof
KR20140100532A (ko) 2011-11-30 2014-08-14 추가이 세이야쿠 가부시키가이샤 면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
WO2013148350A2 (en) * 2012-03-26 2013-10-03 Sanofi Anti-light antibody therapy for inflammatory bowel disease
NO2872646T3 (es) 2012-07-12 2018-01-27
US10259880B2 (en) 2014-01-14 2019-04-16 Kymab Limited Anti-LIGHT antibodies
US20150307620A1 (en) 2014-04-16 2015-10-29 University Of Connecticut Linked immunotherapeutic agonists that costimulate multiple pathways
US10385398B2 (en) * 2015-08-21 2019-08-20 The Children's Hospital Of Philadelphia Methods for use in combination for the treatment and diagnosis of autoimmune diseases
US11312781B2 (en) 2018-01-24 2022-04-26 Capella Bioscience Ltd. Antigen binding molecules that bind LIGHT

Also Published As

Publication number Publication date
BR112022019112A2 (pt) 2022-11-08
EP4126945A2 (en) 2023-02-08
JP2023520216A (ja) 2023-05-16
AU2021248833A1 (en) 2022-09-22
US20240002492A1 (en) 2024-01-04
WO2021202649A3 (en) 2021-11-11
KR102703936B1 (ko) 2024-09-10
WO2021202649A2 (en) 2021-10-07
KR20220161387A (ko) 2022-12-06
TW202204405A (zh) 2022-02-01
EP4126945A4 (en) 2024-02-28
US11708406B2 (en) 2023-07-25
CN115768791A (zh) 2023-03-07
CA3173873A1 (en) 2021-10-07
KR20240135067A (ko) 2024-09-10
US20210324066A1 (en) 2021-10-21
JP7542077B2 (ja) 2024-08-29
CN115768791B (zh) 2024-05-24

Similar Documents

Publication Publication Date Title
BR112018070768A2 (pt) dispositivo de análise de respiração
MA33747B1 (fr) Anticorps monoclonaux diriges contre la progastrine et leurs utilisations
DE602006008774D1 (de) Kanüleneinführungssystem
WO2016201450A3 (en) Cancer treatment and diagnosis
MX2017013390A (es) Método para el tratamiento de cáncer pulmonar.
NZ601111A (en) Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
EA202191133A1 (ru) Сигнатуры интерферона типа i и способы их применения
MX2021007951A (es) Ensayo multiplexado y metodos de uso del mismo.
EA202090673A1 (ru) Стратификация генотипа при лечении и профилактике диабета
MX2022011811A (es) Metodos y tratamiento con exceso de light libre.
MX2021000069A (es) Composiciones y metodos para tratar la enfermedad intestinal inflamatoria.
EA201200991A1 (ru) Способ экспресс-определения атерогенности крови
WO2014100746A3 (en) Tspan 33 is a candidate for antibody targeted therapy for the treatment of b cell hodgkin lymphomas
JP2006517670A5 (es)
MX2021006131A (es) Metodos de tratamiento del sindrome mielodisplasico.
WO2022184942A3 (en) Biomarkers
ATE428437T1 (de) Dc-sign blockern und deren verwendung zur vorbeugung oder behandlung von viraleninfektionen
MX2019013160A (es) Metodos de tratamiento selectivo del asma usando antagonistas de il-17.
MX2022014996A (es) Metodos y tratamiento con anticuerpos contra la il-18.
ES2038597T3 (es) Metodo para detectar anticuerpos neutralizantes de virus en una muestra acuosa.
AR083725A1 (es) Vacunas de enterovirus para prevenir y tratar diabetes tipo 1 (ii)
Wang et al. Trend of the coronavirus disease-2019 epidemic in China after the lockdown of Wuhan City on January 23, 2020
RU2007123817A (ru) Способ оценки фертильности мужчины
Qing Surveillance of human soil⁃ transmitted nematodiasis in Jurong City from 2016 to 2020
MX2022009880A (es) Dispositivos y metodos para tratar la isquemia y sindromes de dificultad respiratoria aguda.